| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.009 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | AICAR | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | Ispinesib Mesylate | GDSC1000 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | AT7867 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.077 | 0.01 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.074 | 0.02 |